CRT Capital Cuts Valeant Pharma (VRX) to Fairly Valued

CRT Capital's Timothy Chiang downgraded shares of Valeant Pharmaceuticals (NYSE: VRX) from Buy to Fairly Valued Thursday afternoon.

The downgrade follows Q1 results from the company and news it will acquire AcneFree and certain assets from University Medical. Shares are down more than 9 percent at last check.

For an analyst ratings summary and ratings history on Valeant Pharmaceuticals click here. For more ratings news on Valeant Pharmaceuticals click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Microsoft invests $1.5 bln in Abu Dhabi AI firm G42, takes board seat
• Amundi and Victory Capital announce plan to establish a strategic partnership:
• BofA Securities Downgrades Charter Hall (CHC:AU) (CTOUF) to Underperform